Diadema Partners »

Altimmune shares owned by Diadema Partners

Quarter-by-quarter ownership of Altimmune (ALT) shares owned by Diadema Partners from 13F filings

Historical chart of Diadema Partners investment in Altimmune

Tip: Access up to 7 years of quarterly data

All positions including Altimmune held by Diadema Partners consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Altimmune by Diadema Partners

Quarter filed Position value Share count Share price at filing
2025-09-30 $1.7M 463k 3.77

More positions owned by Diadema Partners

Jazz Pharmaceuticals Shs Usd (JAZZ)
Soleno Therapeutics (SLNO)
Uniqure Nv SHS Put Option (QURE)
Regeneron Pharmaceuticals (REGN)
Viking Therapeutics (VKTX)
Bristol Myers Squibb (BMY)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
BioMarin Pharmaceutical (BMRN)
Avidity Biosciences Ord (RNA)
Agios Pharmaceuticals Call Option (AGIO)
Ultragenyx Pharmaceutical (RARE)
Incyte Corporation Call Option (INCY)
Intellia Therapeutics Call Option (NTLA)
Vaxcyte (PCVX)
Eli Lilly & Co. Put Option (LLY)

View all positions for Diadema Partners

Top funds holding Altimmune

Vanguard Group
BlackRock
Susquehanna International
State Street Corporation
Tang Capital Management
Citadel Advisors
Geode Capital Management
Two Sigma Investments
Two Sigma Advisers
Knoll Capital Management
Ikarian Capital
UBS Group
Morgan Stanley
Northern Trust
Squarepoint Ops

View all funds holding Altimmune